Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

CTLA-4 and PD-1 Pathways
Elizabeth I. Buchbinder, Anupam M. Desai
American Journal of Clinical Oncology (2015) Vol. 39, Iss. 1, pp. 98-106
Open Access | Times Cited: 1947

Showing 1-25 of 1947 citing articles:

A guide to cancer immunotherapy: from T cell basic science to clinical practice
Alex D. Waldman, Jill M. Fritz, Michael J. Lenardo
Nature reviews. Immunology (2020) Vol. 20, Iss. 11, pp. 651-668
Open Access | Times Cited: 3206
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
Jérôme Galon, Daniela Bruni
Nature Reviews Drug Discovery (2019) Vol. 18, Iss. 3, pp. 197-218
Closed Access | Times Cited: 2622
Non–Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment
Narjust Duma, Rafael Santana-Dávila, Julian R. Molina
Mayo Clinic Proceedings (2019) Vol. 94, Iss. 8, pp. 1623-1640
Closed Access | Times Cited: 1696
Targeting macrophages: therapeutic approaches in cancer
Luca Cassetta, Jeffrey W. Pollard
Nature Reviews Drug Discovery (2018) Vol. 17, Iss. 12, pp. 887-904
Open Access | Times Cited: 1580
Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance
Sreya Bagchi, Robert Yuan, Edgar G. Engleman
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 223-249
Open Access | Times Cited: 1579
Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
Scott Antonia, José A. López-Martín, Johanna C. Bendell, et al.
The Lancet Oncology (2016) Vol. 17, Iss. 7, pp. 883-895
Open Access | Times Cited: 1187
Macrophages in immunoregulation and therapeutics
Shanze Chen, Abdullah F. U. H. Saeed, Quan Liu, et al.
Signal Transduction and Targeted Therapy (2023) Vol. 8, Iss. 1
Open Access | Times Cited: 766
Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment
Xingzhe Ma, Enguang Bi, Yong Lu, et al.
Cell Metabolism (2019) Vol. 30, Iss. 1, pp. 143-156.e5
Open Access | Times Cited: 673
Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma
Noam Auslander, Gao Zhang, Joo Sang Lee, et al.
Nature Medicine (2018) Vol. 24, Iss. 10, pp. 1545-1549
Open Access | Times Cited: 619
Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways
Lukas Kraehenbuehl, Chien‐Huan Weng, Shabnam Eghbali, et al.
Nature Reviews Clinical Oncology (2021) Vol. 19, Iss. 1, pp. 37-50
Closed Access | Times Cited: 585
Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial
Manish R. Patel, John Ellerton, Jeffrey R. Infante, et al.
The Lancet Oncology (2017) Vol. 19, Iss. 1, pp. 51-64
Open Access | Times Cited: 560
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan, Robert S. Kerbel
Nature Reviews Clinical Oncology (2018) Vol. 15, Iss. 5, pp. 310-324
Closed Access | Times Cited: 527
DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy
Ruixue Huang, Ping‐Kun Zhou
Signal Transduction and Targeted Therapy (2021) Vol. 6, Iss. 1
Open Access | Times Cited: 511
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Silvia Vivarelli, Rossella Salemi, Saverio Candido, et al.
Cancers (2019) Vol. 11, Iss. 1, pp. 38-38
Open Access | Times Cited: 496
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Mihe Hong, Justin Clubb, Yvonne Y. Chen
Cancer Cell (2020) Vol. 38, Iss. 4, pp. 473-488
Open Access | Times Cited: 484
Immune checkpoints and their inhibition in cancer and infectious diseases
Lydia Dyck, Kingston H. G. Mills
European Journal of Immunology (2017) Vol. 47, Iss. 5, pp. 765-779
Open Access | Times Cited: 480
Safety and Efficacy of Nivolumab in Combination With Ipilimumab in Metastatic Renal Cell Carcinoma: The CheckMate 016 Study
Hans J. Hammers, Elizabeth R. Plimack, Jeffrey R. Infante, et al.
Journal of Clinical Oncology (2017) Vol. 35, Iss. 34, pp. 3851-3858
Open Access | Times Cited: 462
Tumor Immunology and Tumor Evolution: Intertwined Histories
Jérôme Galon, Daniela Bruni
Immunity (2020) Vol. 52, Iss. 1, pp. 55-81
Open Access | Times Cited: 457
Next generation of immune checkpoint inhibitors and beyond
Julian A. Marin‐Acevedo, ErinMarie O. Kimbrough, Yanyan Lou
Journal of Hematology & Oncology (2021) Vol. 14, Iss. 1
Open Access | Times Cited: 447
Regulatory T Cells in the Tumor Microenvironment and Cancer Progression: Role and Therapeutic Targeting
Belal Chaudhary, Eyad Elkord
Vaccines (2016) Vol. 4, Iss. 3, pp. 28-28
Open Access | Times Cited: 436
Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy
Ri‐Yao Yang, Linlin Sun, Ching-Fei Li, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 418
Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC)
Young Kwang Chae, Ayush Arya, Wade T. Iams, et al.
Journal for ImmunoTherapy of Cancer (2018) Vol. 6, Iss. 1
Open Access | Times Cited: 390
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
C. Pettenati, Molly A. Ingersoll
Nature Reviews Urology (2018) Vol. 15, Iss. 10, pp. 615-625
Closed Access | Times Cited: 386
Safety, Efficacy, and Pharmacodynamics of Tremelimumab Plus Durvalumab for Patients With Unresectable Hepatocellular Carcinoma: Randomized Expansion of a Phase I/II Study
Robin Kate Kelley, Bruno Sangro, William Proctor Harris, et al.
Journal of Clinical Oncology (2021) Vol. 39, Iss. 27, pp. 2991-3001
Open Access | Times Cited: 368
CAR-T cells: the long and winding road to solid tumors
Maria Michela D’Aloia, Ilaria Grazia Zizzari, Benedetto Sacchetti, et al.
Cell Death and Disease (2018) Vol. 9, Iss. 3
Open Access | Times Cited: 362
Page 1 - Next Page

Scroll to top